enGene Therapeutics (ENGN) Non Operating Interest Expenses (2023 - 2026)

enGene Therapeutics (ENGN) has 4 years of Non Operating Interest Expenses data on file, last reported at $843000.0 in Q3 2026.

• For the quarter ending Q3 2026, Non Operating Interest Expenses rose 11.21% year-over-year to $843000.0; the trailing twelve-month figure through Jul 2026 stood at $3.1 million (up 2.33% YoY), and the FY2025 full-year result was $3.0 million, up 7.01% from the prior year.
• Non Operating Interest Expenses was $843000.0 for Q3 2026 at enGene Therapeutics, up from $745000.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $1.4 million in Q3 2023 to a low of $563000.0 in Q1 2024.
• A 4-year average of $871000.0 and a median of $752000.0 in 2025 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses slumped 52.09% in 2024 and soared 33.57% in 2025, its largest moves.
• enGene Therapeutics' Non Operating Interest Expenses stood at $1.2 million in 2023, then slumped by 34.77% to $756000.0 in 2024, then decreased by 0.79% to $750000.0 in 2025, then grew by 12.4% to $843000.0 in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $843000.0 in Q3 2026, $745000.0 in Q2 2026, and $732000.0 in Q1 2026.